

Ocugen shares continue to ride COVID wave as Bharat data hints vaccine protects against Indian variant

BY SANDI WONG, ASSISTANT EDITOR AND GUNJAN OHRI, STAFF WRITER

Another COVID vaccine milestone has Ocugen shares gaining more than double digits Monday, as the company reported data suggesting Covaxin can protect against variants including B.1.617, which is implicated in India's current COVID-19 wave.

Shares of Ocugen Inc. (NASDAQ:OCGN) had held fairly steady since the company went public through a reverse merger in September 2019 with Histogenics Corp.


A February deal with Bharat Biotech International Ltd. that gave Ocugen exclusive U.S. rights to Covaxin (BBV152), quickly followed by a registered direct offering sold at a 46% premium,

provided the company's stock with a spark that carried its market cap to \$3 billion.

Now, data showing Covaxin-induced sera can neutralize B.1.617 as well as the B.1.128 variant first identified in Brazil has the stock up 24% to \$15.68 for a valuation of \$3.1 billion.

A bioRxiv paper published April 23 reported that sera from 28 people immunized with Covaxin had less than twofold drops in neutralization potency against B.1.617 vs. B.1.1.7 (U.K.) or a prototype variant ($p < 0.0001$ for both). An Indian Council of Medical Research (ICMR)-National Institute of Virology team

Ocugen's share price since 2020



BIOCENTURY

conducted the study, which found no statistically significant difference in titers against B.1.1.7 and the prototype variant.

On Monday, Ocugen announced additional data from the study showing a similarly small drop in the ability to neutralize B.1.128.

The inactivated SARS-CoV-2 vaccine gained emergency approval from the Drugs Controller General of India (DCGI) in January, before a Phase III efficacy readout, based on in vitro neutralization data from Phase I and II studies.

An interim Phase III readout in March showed Covaxin was 80.6% protective in a Phase III trial based on 43 cases. A second interim analysis based on 127 cases, reported April 28, demonstrated 78% efficacy against mild or worse COVID-19.

B.1.617 contains an E484Q mutation — at the same site as a key mutation B.1.128, B.1.351 (South Africa) and B.1.526 (New York) — as well as the L452R mutation in B.1.427/B.1.429 (California).

BIOCENTURY INC.

BioCentury's mission is to provide value-added business intelligence & analysis for life science companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures.

NEWSROOM

news@biocentury.com

SAN CARLOS, CA

+1 650-595-5333; Fax: +1 650-595-5589

CHICAGO

+1 312-755-0798; Fax: +1 650-595-5589

WASHINGTON, DC

+1 202-462-9582; Fax: +1 202-667-2922

UNITED KINGDOM

+44 (0)1865-512184; Fax: +1 650-595-5589

BioCentury®; Because Real Intelligence is Hard to Find™; BCIQ™; The BioCentury 100™; and The Clear Route to ROI™ are trademarks of BIOCENTURY INC. All contents Copyright © 2021, BIOCENTURY INC. ALL RIGHTS RESERVED. No part of BioCentury's Publications or Website may be copied, reproduced, retransmitted, disseminated, sold, distributed, published, broadcast, circulated, commercially exploited in any form or used to create derivative works without the written consent of BioCentury. Information provided by BioCentury's Publications and Website is gathered from sources that BioCentury believes are reliable; however, BioCentury does not guarantee the accuracy, completeness, or timeliness of the information, nor does BioCentury make any warranties of any kind regarding the information. The contents of BioCentury's Publications and Website are not intended as investment, business, tax or legal advice, and BioCentury is not responsible for any investment, business, tax or legal opinions cited therein or for any decision made or action taken in reliance upon such information.

All use of BioCentury and its contents by current subscribers is governed by the BioCentury User Agreement and by all others is governed by the BioCentury Terms of Use, unless a written agreement to the contrary has been executed by BioCentury Inc.

USE OF IMAGES: Certain Images used in BioCentury Inc.'s Publications, Video Content, Websites, Services, Notices and/or Marketing Materials are licensed from Getty Images (US), Inc. Any such image of a person or object so displayed is being used for illustrative purposes only and any such person or object depicted, if any, is merely a model. For more information see "Use of Images" found under the "Legal" section on the footer of the homepage at www.biocentury.com.

PRIVACY & ADVERTISING: In accordance with its Privacy Policy, BioCentury does NOT sell its customer information or usage data to third parties. BioCentury sells advertising in its BioCentury product emails and on its website. BioCentury is pleased to acknowledge its conference and events partners and sponsors through promotional announcements, on our web site, at our events and in our product emails. BioCentury also provides advertising opportunities to partners, sponsors, and advertisers through stand-alone emails to our community.